Drug Profile


Alternative Names: EBI 005 1; EBI 005 2; EBI-005

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eleven Biotherapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Peptides; Proteins
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 01 May 2016 Adverse events and efficacy data from preclinical studies in Dry eye disease released by Eleven Biotherapeutics (3184998; 9195137)
  • 01 May 2016 Adverse events data from preclinical studies in Allergic conjunctivitis released by Eleven Biotherapeutics (3184996; 9195137)
  • 16 Feb 2016 Discontinued - Phase-III for Allergic conjunctivitis in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top